Navigation Links
Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
Date:9/2/2008

nts studied in ATHENA were either 75 years of age or older (with or without cardiovascular risk factor) or above 70 years of age with at least one additional cardiovascular risk factor (hypertension, diabetes, previous cerebrovascular event, left atrium size greater than 50 mm or left ventricular ejection fraction lower than 40%). Patients were randomized to receive Multaq(R) 400 mg BID or placebo, with a maximum follow-up of 30 months.

The ATHENA study objectives were to show a potential benefit of Multaq(R) on the primary composite endpoint of all-cause mortality combined with cardiovascular hospitalization as compared to placebo. The pre-specified secondary endpoints were death from any cause, cardiovascular death and hospitalisation for cardiovascular reasons. The pre-specified safety endpoint was the incidence of treatment emergent adverse events (between first study drug intake and last study drug intake plus 10 days) including: all adverse events, serious adverse events, adverse events leading to study drug discontinuation.

The ATHENA stroke post-hoc analysis on a non-pre-specified secondary endpoint was conducted in order to confirm the consistent benefit of Multaq(R) in atrial fibrillation or atrial flutter patients in reducing major cardiovascular complications like stroke, which is a leading cause of cardiovascular hospitalizations or death in this patient population.

About Multaq(R) (dronedarone)

Multaq(R) is an investigational treatment and the only anti-arrhythmic drug (AAD) to have shown a significant reduction in morbidity and mortality in atrial fibrillation /atrial flutter patients with a favourable safety profile as evidenced by a low incidence of pro-arrhythmia (including torsades de pointes) and extra-cardiac organ toxicity.

Multaq(R), discovered and developed by sanofi-aventis, has been studied in a clinical development program including more than 7,000 patients. Multaq(R) is one of the major therapeutic innov
'/>"/>

SOURCE Sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
2. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
3. Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies
4. Published Guidelines Further Support Use of Bioimpedance Measurement Technology for Early Assessment of Lymphedema
5. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
6. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
7. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
8. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
9. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
10. Arpida Provides Further Comments on the Pivotal Phase III Trials
11. Molecular Science Could Further Improve Leukemia Survival, Say St. Jude Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... According to a new market ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 ... of 10.1% from 2014 to 2020. Biological ... used in the treatment and prevention of various diseases ... medical disorders. Biological drugs include therapeutic proteins, monoclonal antibody ...
(Date:9/2/2014)... Calif. , Sept. 2, 2014 /PRNewswire-iReach/ -- ... just recognized as one of the fastest growing ... past few years, the company has undergone significant ... research, late phase global clinical development, anti-viral and ... 2 years, WCCT Global has successfully participated in ...
(Date:9/1/2014)... 1, 2014 Research and Markets ... Minimally-Invasive Biomarkers in Alzheimer,s Disease: A Comprehensive Analysis and ... report to their offering. This report ... developments relating to early-stage minimally-invasive biomarkers in Alzheimer,s disease, ... and candidates in the AD drug pipeline, and applicable ...
Breaking Medicine Technology:CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 2CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 3CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 4CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 5CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 6Contract Research Organization WCCT Global Celebrates Being Named as One of the Fastest Growing Companies in America 2Early-Stage Minimally-Invasive Biomarkers in Alzheimer's Disease: A Comprehensive Analysis and Market Study of New Developments and Opportunities, 2014 2
... ANX ) today announced that the U.S. Food and Drug Administration (FDA) has accepted the proposed proprietary name "Exelbine™" for the Company,s product candidate ANX-530 (vinorelbine injectable emulsion). , ... , ... ... ...
... Ardea Biosciences, Inc. (Nasdaq: RDEA ) a biotechnology company focused on the development of small-molecule ... fourth quarter and full-year 2009 financial results and provided key upcoming clinical development milestones and financial guidance ... ... , ...
Cached Medicine Technology:ADVENTRX Receives Brand Name Acceptance for ANX-530 2ADVENTRX Receives Brand Name Acceptance for ANX-530 3ADVENTRX Receives Brand Name Acceptance for ANX-530 4Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 2Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 3Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 4Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 5Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 6Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 7Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 8Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 9Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 10Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 11
(Date:9/2/2014)... Recently, Os-Monitor.com, an innovative company that provides many ... of employee internet monitoring products ( http://www.os-monitor.com ). Furthermore, ... to 10% off, on these useful items. , ... 20 different kinds of high end monitoring programs on ... companies of all sizes. With its high end programs, ...
(Date:9/2/2014)... A simple awareness campaign in general practice identifies new ... at ESC Congress today by Professor Jean-Marc Davy from ... the most common cardiac arrhythmia. It multiplies the risk ... of stroke risk by five-fold. Similarly, AF is responsible ... AF is often overlooked and diagnosed too late. In ...
(Date:9/2/2014)... Developers and plugin specialist of Final Cut ... from Pixel Film Studios. , “ProIntro has enabled users ... Christina Austin, CEO of Pixel Film Studios. “Blurring the ... game changer.” , Learn how to create a title ... Studios. ProIntro is a package of professionally designed titles ...
(Date:9/2/2014)... FL (PRWEB) September 02, 2014 ... for about a decade, primarily to help people ... time, there are three developed systems,” says Dana ... approaches substantively differ, the goals are much the ... support of some type of harmonica.” , The ...
(Date:9/2/2014)... AURO the enterprise Canadian Public ... expansion of its leadership team with the appointment of ... Liang joins AURO in conjunction with his current role ... with the operations, product management and engineering teams to ... well as ensuring effective internal and external controls are ...
Breaking Medicine News(10 mins):Health News:Useful Employee Internet Monitoring Products Now For Sale At Os-Monitor.com 2Health News:Simple awareness campaign in general practice identifies new cases of AF 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 3Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 3Health News:AURO Appoints Kevin Liang as New Chief Financial Officer for Canadian Enterprise Public Cloud 2Health News:AURO Appoints Kevin Liang as New Chief Financial Officer for Canadian Enterprise Public Cloud 3
... new study finds that, despite efforts in the last ... significantly less likely than white patients to receive therapy ... study conclude that efforts to close treatment gaps initiated ... The report appears in the February 15, 2008 issue ...
... Conn., Jan. 6 Therap Services, the leading,provider ... has announced the promotion of Allison Dudo to ... responsibility of,providing help and technical guidance to users ... key part of our success, and we were ...
... heavily than male peers, field study finds , , SUNDAY, ... of college drinking behavior shows that parties with drinking ... parties encourage college women to drink more heavily than ... drinking have relied largely on individual behavior and self-reports ...
... Year,s,resolution is to lose weight, calcium and dairy can help, ... Science Hawley,Almstedt and her student Alexandra Hybki. The everyday nutrients ... down this year., People on fad diets or extreme ... foods are high in fat. Some dieters go,so far as ...
... Holdings, Inc. President Robert Oswald provides a shareholder,update., ... as we opened 5 new,locations across Canada, including the ... were fortunate to have our Official Spokesperson,for Canada, Mr. ... opening,events for our new locations. I was very pleased ...
... radiation after early-stage disease is removed, researchers say , FRIDAY, ... have not yet spread contain cells with a predisposition to ... just because a cancer has not yet spread doesn,t mean ... warned researchers at the Salk Institute for Biological Studies in ...
Cached Medicine News:Health News:Racial disparities persist in cancer care 2Health News:Therap Services Promotes Allison Dudo to Assistant Director of Training 2Health News:College Drinking Games Lead to Higher Blood Alcohol Levels 2Health News:Milk Does a Body and a Waistline Good 2Health News:HearAtLast Holdings, Inc. Provides Shareholder Update 2Health News:HearAtLast Holdings, Inc. Provides Shareholder Update 3Health News:HearAtLast Holdings, Inc. Provides Shareholder Update 4Health News:HearAtLast Holdings, Inc. Provides Shareholder Update 5Health News:Localized Breast Cancer Cells Have Potential to Spread 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: